CTOs on the Move

Paddock Laboratories Inc

www.paddocklabs.com

 
Paddock Laboratories is a privately-held niche-based pharmaceutical company located in Minneapolis, Minnesota. Bruce Paddock, President, founded the business in 1977 with only three employees. Today, Paddock employs over 250 people in the areas of
  • Number of Employees: 5K-10K
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

Proneuron Biotechnologies

Proneuron Biotechnologies is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Regulatory Professionals Inc

Regulatory Professionals Inc is a Milpitas, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

WCG Clinical Services

WCG is the world`s largest and most trusted provider of regulatory and ethical review services for human research. The pioneer of independent ethical review, WCG continues to drive ingenuity in the clinical research space. Today, WCG`s solutions are built upon the foundation of ethical review, but have grown to include a suite of complementary services and technologies that expand the capabilities of the modern research professional. WCG delivers transformational solutions that stimulate growth, foster compliance, and maximize efficiency for those who perform clinical trials. WCG is proud to serve the individuals on the frontlines of science and medicine, and the organizations that strive to develop new products and therapies to improve the quality of human health. It is our role to empower them to accelerate advancement, while ensuring that the risks of progress never outweigh the value of human life.

Acerta Pharma B.V.

Acerta Pharma is a leader in the field of covalent binding technology and is applying this technology to create novel, highly selective therapies for cancer.

Olema

Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer. At Olema we leverage the exquisite knowledge of the molecular action of the ER to design compounds that are superior to both the current drugs and those in development.